Clin Cancer Res: Co-use of Samisson reduces clinical benefits for patients with glioma who receive immunotherapy

Dexomisone is a powerful glucocorticoid, its pharmacological effect is mainly anti-inflammatory, anti-toxic, anti-allergic, anti-rheumatoid, clinical use is more extensive.
also commonly used in patients with brain tumors to reduce tumor-related cerebral edema.
years, immuno-checkpoint inhibitors, as a new cancer treatment, have been studied and applied in glioma treatment.
, however, there is a lack of sufficient clinical data on the safety and effectiveness of simultaneous use of dexamymethon in patients with cerebral glioma treated with immuno-checkpoint inhibitors.
, a paper published in the journal Clinical Cancer Research reported that in patients with glioblastoma (GBM) who received immunosuppressants, the overall survival rate of patients treated with dexamisong at the baseline of cerebral edema decreased significantly.
the authors first studied in animal experiments, and when the mice were treated with PD-1 inhibitor antibodies alone, most mice were cured, while when the combined synthesizer was treated, the clinical benefits of anti-PD-1 therapy were significantly reduced by the dose dependence of dexamisong.
the survival of mice with anti-PD-1 monoantigen therapy showed a decrease in dose dependence of dexamissong in the anti-PD-1 monodrative treatment group with an OS rate of about 76% at 100 days of treatment; The OS rate is 47 per cent when 1mg/kg is given, 31 per cent when 2.5mg/kg is given and 27 per cent when 10 mg/kg is given.
Analysis of immune cells in the spleen in the subject showed that dexemisse can reduce the level of T cells in the spleen and systemic T cells, natural killer cells and myelin cells, and significantly impair the function of lymphocytes.
authors also said T-cell depletion could be observed in mice an hour after the dexamisong injection.
, the authors assessed the overall survival data of 181 glioblastoma patients treated with anti-PD-1 or anti-PD-L1 at the Dana-Farber Cancer Institute prior to April 1, 2019.
Through statistical analysis of multiple variables including age, performance status, degree of excision, tumor size, large tumor burden, and MGMT promoter methylation status, the results showed that patients who received dexomysund at baseline were about twice as likely to die as those who were not taken at baseline.
addition, baseline use of dexamisson is the most negative risk factor for determining the overall survival rate.
the authors say that while the clinical study is retrospective and has limitations, these results suggest that we should avoid the use of dexymission in patients treated with glioblastoma with immunotherapy and, if necessary, consider giving the lowest dose and the shortest amount of time to use it.
the same effect on other immunotherapies is still to be studied.
。